✦ LIBER ✦

Sa1241 Pharmacology of Etrolizumab in a Phase 2 Study in Moderate-to-Severely Active Ulcerative Colitis

✍ Scribed by Looney, Caroline; Fuh, Franklin; Tang, Meina T.; Wei, Xiaohui; Keir, Mary E.; Tew, Gaik W.; Eastham-Anderson, Jeffrey; Diehl, Lauri; Salas, Azucena; De Hertogh, Gert; Francom, Steven; Gilbert, Houston; Luca, Diana; Egen, Jackson G.; Vermeire, Severine; Mansfield, John C.; Lamb, Christopher A.; Feagan, Brian G.; Panes, Julian; Baumgart, Daniel C.; Schreiber, Stefan; Dotan, Iris; Sandborn, William; Rutgeerts, Paul J.; Lu, Timothy; O'Byrne, Sharon; Williams, Marna

Book ID: 122335800
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 108 KB
Volume: 146
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(14)60845-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sa1204 Pharmacokinetics of Adalimumab in

Sa1204 Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

✍ Awni, Walid M.; Eckert, Doerthe; Sharma, Shringi; Mostafa, Nael M.; Noertersheus 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 170 KB

OP010 AlphaE integrin expression as a pr

OP010 AlphaE integrin expression as a predictive biomarker for induction of clinical remission by etrolizumab: Analysis of a phase II trial in moderate-to-severely active ulcerative colitis

✍ Keir, M.; Tew, G.W.; Luca, D.; Eastham-Anderson, J.; Diehl, L.; Egen, J.G.; Verm 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 54 KB

Su1276 αE Integrin Expression As a Predi

Su1276 αE Integrin Expression As a Predictive Biomarker for Induction of Clinical Remission by Etrolizumab: Analysis of a Phase II Trial in Moderate-to-Severely Active Ulcerative Colitis

✍ Keir, Mary E.; Tew, Gaik Wei; Luca, Diana; Eastham-Anderson, Jeffrey; Diehl, Lau 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 242 KB

A Phase I Study of rHuMab Beta7 in Moder

A Phase I Study of rHuMab Beta7 in Moderate to Severe Ulcerative Colitis (UC)

✍ Paul J. Rutgeerts; Richard N. Fedorak; Daniel W. Hommes; Andreas Sturm; Daniel C 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Sa1203 Pharmacokinetics and Exposure-Res

Sa1203 Pharmacokinetics and Exposure-Response Relationship of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase2/3 Induction and Maintenance Studies

✍ Adedokun, Omoniyi J.; Xu, Zhenhua; Marano, Colleen W; Strauss, Richard; Zhang, H 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 319 KB

159 Differentiation Between Etrolizumab

159 Differentiation Between Etrolizumab (Rhumab Beta7) and Placebo in the Eucalyptus Phase II Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate Efficacy and Safety in Patients With Refractory Moderate-to-Severely Active Ulcerative Colitis

✍ Vermeire, Severine; O'Byrne, Sharon; Williams, Marna; Mansfield, John C.; Feagan 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 434 KB